Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
6th
years
Home>>Products>>CAS 366789-02-8 99% Rivaroxaban Powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile: +8615207100586

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

CAS 366789-02-8 99% Rivaroxaban Powder

CAS NO.366789-02-8

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,
Contact Supplier

Product Details

Keywords

  • Rivaroxaban powder
  • Rivaroxaban
  • 99% Rivaroxaban Powder

Quick Details

  • ProName: CAS 366789-02-8 99% Rivaroxaban Powder
  • CasNo: 366789-02-8
  • Molecular Formula: C19H18ClN3O5S
  • Appearance: white
  • Application: anti antiviral
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Day
  • Purity: 99
  • Storage: room
  • LimitNum: 1 Kilogram

Superiority

 

MOQ: 10g
Form: Powder
Colour: White
Test: HPLC
Function: anti  antiviral 
Grade: Pharm

 

Details

CAS 366789-02-8 99% Rivaroxaban Powder 

product Name:    Rivaroxaban
CAS:    366789-02-8
MF:    C19H18ClN3O5S
MW:    435.88
EINECS:    685-132-2 

What is Rivaroxaban
Anticoagulants in adults with non-valvular atrial fibrillation (other than rheumatic valvular heart disease and atrial fibrillation after heart valve replacement) to reduce the risk of stroke and systemic embolism

Rivaroxaban  Function
Rivaroxaban is also a drug for the prevention and treatment of venous thrombosis. Clinically, it is mainly used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement.